Baxdrostat - How high blood pressure wonder drug could be a game changer

A new experimental drug is being hailed as a potential game-changer in the fight against high blood pressure which is one of the leading risk factors for heart disease and stroke across the globe. Early clinical trials have shown promising results, with researchers optimistic that the treatment could offer a more effective and safer alternative to existing medications.

For patients and doctors, high blood pressure that resists multiple medications remains a constant challenge. According to the study published in ‘The New England Journal of Medicine’, a new pill, Baxdrostat, offers a fresh approach by lowering a hormone that drives blood pressure up.

According to earth.com, Baxdrostat has been designed specifically for people who have consistent high blood pressure levels despite taking a careful mix of standard drugs. It basically works by targeting a critical biological switch while not affecting other essential hormones, making it a viable option for hard-to-treat hypertension.

HOW BAXDROSTAT CONTROLS HIGH BLOOD PRESSURE

Many people have been affected by 'resistant hypertension' globally. It's a common term used for the patients whose blood pressure shoots above specified limit on a regular basis despite taking three or more medicines, including a water pill, and because of that the health risks stack up in quick time.

The main cause to reach this state is aldosterone, a hormone that signals the kidneys to retain salt and water. Excess aldosterone boosts blood volume, narrows blood vessels, and drives pressure up.

According to earth.com, Baxdrostat works by blocking aldosterone synthase, the enzyme responsible for producing aldosterone, thereby lowering its levels. Early studies showed it reduces aldosterone without affecting cortisol - a vital hormone for stress, inflammation, and metabolism.

Unlike traditional mineralocorticoid receptor blockers, used by doctors, which counter aldosterone but often cause high potassium and other side effects, Baxdrostat offers a more targeted, potentially safer solution.

WHAT IS BAXHTN?

BaxHTN is a global randomised trial that tested Baxdrostat at doses of 1 milligram and 2 milligrams against a placebo, all added to standard therapy over 12 weeks. The study enrolled adults whose blood pressure remained elevated despite routine treatment.

At baseline, participants had seated systolic readings between 140 and 170 millimeters of mercury. They represented mainly two categories: Patients uncontrolled on two drugs, and those resistant despite three or more medications, including a diuretic.

BAXDROSTAT DROPS HYPERTENSION

After 12 weeks, the BaxHTN trial demonstrated significantly greater reductions in seated systolic blood pressure with Baxdrostat compared to placebo. The 1mg dose lowered systolic pressure by 8.7 of mercury, while the 2mg dose produced a 9.8 of mercury drop.

These improvements came on top of existing therapies, an important finding for patients already on multiple medications.

According to the study, as quoted by earth.com, rates of confirmed hyperkalemia - potassium levels above 6.0 mmol/L - were 2.3% with 1mg, 3.0% with 2mg, and 0.4% with placebo.

IS BAXDROSTAT SAFE?

Any drug that reduces aldosterone can raise potassium levels, and the BaxHTN trial safety data confirmed that this risk is present. However, most cases were manageable with routine monitoring and dose adjustments.

Clinicians are already accustomed to tracking potassium in patients on ACE inhibitors or certain diuretics. The same approach applies here, particularly for individuals with kidney disease or those using potassium-boosting supplements, ensuring safe use while reaping the blood pressure benefits.

HOW BAXDROSTAT MAKES A DIFFERENCE

Even small reductions in systolic blood pressure make a big difference in lowering the long-term risk of heart attack, stroke, heart failure, and kidney disease. A treatment that consistently lowers pressure by about 9 to 10 millimeters of mercury on top of standard therapy could be transformative, helping many patients finally reach target levels.

"Achieving a nearly 10 mm Hg placebo-adjusted reduction in systolic blood pressure with Baxdrostat in the BaxHTN phase 3 trial is exciting," Bryan Williams, who is the primary study investigator and a leading hypertension specialist, told earth.com.

"This level of reduction is linked to substantially lower risk of heart attack, stroke, heart failure, and kidney disease," Williams, MD, chair of medicine at University College London, added.

Baxdrostat is aimed at people whose blood pressure remains above 140 millimeters of mercury despite carefully managed combinations of medications. It could be especially valuable for patients with a strong aldosterone drive who struggle with high-dose mineralocorticoid receptor blockers.

Research also suggests it may help those with nighttime blood pressure surges, often linked to aldosterone. For now, it remains experimental, available only in clinical trials until regulatory review is complete.

Once it clears mandatory regulatory approvals, Baxdrostat has the potential to be a true game changer in hypertension care. By offering meaningful blood pressure reductions, it could give new hope to patients who have long struggled with resistant hypertension.